Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Acorda Therapeutics, Inc. ("Acorda" or the "Company") ACOR.
On August 29, 2017, Acorda announced that it had received a Refusal to File letter from the U.S. Food and Drug Administration ("FDA"), which informed the Company that its New Drug Application for INBRIJA (CVT-301) "was not sufficiently complete to permit a substantive review."
On this news, Acorda's share price significantly declined.
If you invested in Acorda stock or options between February 9, 2017 and August 28, 2017 and would like to discuss your legal rights, click here: www.faruqilaw.com/ACOR. There is no cost or obligation to you.
You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170905006552/en/
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
